Liege, Belgium, 28 February 2022 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Mr. François Fornieri, on 26 February 2022.

Liege, Belgium, 25 February 2022 – 7:35 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Alychlo NV, having its registered seat located at Lembergsesteenweg 19, 9820 Merelbeke, on 24 February 2022.

Liege, Belgium, 25 February 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Goldman Sachs Group, Inc., with registered offices at Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, USA, on 22 February 2022.

Liege, Belgium, 21 February 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health announces that it will host a live webcast on Tuesday, 8 March 2022 at 09:00 CET to present its 2021 financial and operating results.

The live webcast can be accessed on the Mithra website or by clicking here. A replay of the webcast will be available on Mithra investor’s website shortly after the close of the call.

LIEGE (Belgium – 7:30 AM CET) and MONTREAL (Canada – 7:00 AM EST), February 16, 2022 – Mithra and Searchlight Pharma are pleased to announce the commercial launch of Mithra’s vaginal contraceptive ring Myring® under the brandname Haloette® in Canada.

Liege, Belgium, 16 February 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it has received today a rectification concerning the transparency notification of Mr. François Fornieri dated January 7, 2022 and published in a press release on January 10, 2022.

 

Liege, Belgium, 14 February 2022 – 17:45 CET – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 442,191 new shares today for a total amount of EUR 8,061,142 following the Put Option Notice issued on 20 December, 2021 in the framework of LDA capital commitment agreement.

Liege, Belgium, 7 February 2022 – 07:30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that it has entered into an equity financing agreement with Goldman Sachs International (“GSI”), pursuant to which the Company can at its sole discretion require GSI (subject to certain conditions) to provide funding to the Company for an aggregate amount of up to EUR 100,000,000 (the “Committed Amount”) in return for issuing GSI with call options over the Company’s ordinary shares. The arrangement has been entered into for a term of approximately 2 years.